The global cytotoxic drugs market is estimated to grow at a CAGR of nearly 1.3% during the forecast period. Significant rise in cancer incidences has led the demand for chemotherapy which utilizes specialized medications to reach and kill cancer cells in a part of the body, rather than surgery and radiation, which target particular areas. As per the World Health Organization (WHO), in 2018, the cancer burden across the globe is anticipated to have increased to 18.1 million new incidences and 9.6 million mortalities. Globally, one in 5 men and one in 6 women develop cancer in their lifetime. Globally, 43.8 million patients were suffering from cancer in 2018.
To Request a Free Sample of our Global Cytotoxic Drugs Market: https://www.omrglobal.com/request-sample/cytotoxic-drugs-market
Chemo is regarded as a systemic treatment as the drugs travel in all over the body and kill cancerous cells that have spread to body parts far away from the primary tumor, which makes it different from other cancer treatments such as radiation and surgery. Surgery is used for tumor removal from a body part where cancer has been detected. Radiation therapy is intended at a certain area of the body to damage or kill cancerous cells. These are known as local treatments as they affect one part of the body. Chemotherapy involves the use of cytotoxic drugs to kill cancer cells. These drugs restrict the division of cells and thereby kills cancerous cells. The therapy can be potential outside the primary tumor as well as destroy small tumors that have not been identified in tests.
Several kinds of cytotoxic drugs are utilized in cancer therapy and the professionals administer a combination of multiple different cytotoxic drugs. The chemotherapy effectiveness relies on the kind of tumor, tumor development rate and its composition, as well as the proportion of cells in the distribution stage. Owing to the potential role of cytotoxic drugs in chemotherapy, the pharmaceutical companies are focusing on launching new cytotoxic drugs for more reliable and effective treatment of cancer diseases. For instance, in April 2020, Intensity Therapeutics signed a clinical trial partnership agreement with Bristol Myers Squibb Co. This program aims to assess the safety and efficacy of the lead product of Intensity referred to as INT230-6. It is a new anti-cancer drug under investigation which is intended to directly kill cancerous cells with intratumoral injection.
In addition, it aims to improve immune cell recognition of cancer, while offered in combination with Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) immune checkpoint inhibitor Yervoy (ipilimumab) of Bristol Myers Squibb. This combination will be assessed among patients suffering from advanced sarcoma, liver cancer, and breast cancer, in a range of new cohorts under IT-01, current Phase 1/2 clinical trial of Intensity. Bristol Myers Squibb will supply Yervoy for the study and Intensity will sponsor and conduct the clinical trial. Such kinds of clinical studies will offer an opportunity for the introduction of combined therapies for the treatment of cancer, which in turn, will likely drive the global cytotoxic drugs market.
(Get 15% Discount on Buying this Report)
A full Report of Global Cytotoxic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/cytotoxic-drugs-market
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
